Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma

Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable anti-tumor activities in the preclinical setting; however, their clinical utility is limited due to unfavo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Minami, Jiro, Suzuki, Rikio, Mazitschek, Ralph, Gorgun, Gullu, Ghosh, Balaram, Cirstea, Diana, Hu, Yiguo, Mimura, Naoya, Ohguchi, Hiroto, Cottini, Francesca, Jakubikova, Jana, Munshi, Nikhil C., Haggarty, Stephen J., Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4165599/
https://ncbi.nlm.nih.gov/pubmed/23913134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.231
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados